Premium
Daily phosphodiesterase type 5 inhibitor therapy: a new treatment option for prostatitis/prostatodynia?
Author(s) -
Kirby Roger S.,
Carson Culley,
Dasgupta Prokar
Publication year - 2015
Publication title -
trends in urology and men's health
Language(s) - English
Resource type - Journals
eISSN - 2044-3749
pISSN - 2044-3730
DOI - 10.1002/tre.462
Subject(s) - prostatitis , medicine , pelvic pain , cgmp specific phosphodiesterase type 5 , chronic bacterial prostatitis , tadalafil , ciprofloxacin , urology , prostate , surgery , antibiotics , erectile dysfunction , cancer , microbiology and biotechnology , biology
The management of patients with chronic pelvic pain attributed to chronic prostatitis has always been rather unsatisfactory. Even prolonged treatment with an aminoquinolone, such as ciprofloxacin, and an anti‐inflammatory agent, or, alternatively an alpha‐blocker, seldom results in rapid resolution of the symptoms, and is commonly completely ineffective.